XML 40 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Financial Instruments and Fair Value Measurements (Tables)
 3 Months Ended
Apr. 01, 2022
Fair Value Disclosures [Abstract]  
Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis
The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:

April 1,
2022
Quoted Prices in Active Markets for Identical Assets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Assets:
Debt and equity securities held in rabbi trusts
$36.9 $24.7 $12.2 $— 
Equity securities
32.4 32.4 — — 
$69.3 $57.1 $12.2 $— 
Liabilities:
Deferred compensation liabilities$29.3 $— $29.3 $— 
Contingent consideration liabilities27.2 — — 27.2 

$56.5 $— $29.3 $27.2 
December 31,
2021
Quoted Prices in Active Markets for Identical Assets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Assets:
Debt and equity securities held in rabbi trusts$38.7 $24.9 $13.8 $— 
Equity securities36.5 36.5 — — 
$75.2 $61.4 $13.8 $— 
Liabilities:
Deferred compensation liabilities$36.9 $— $36.9 $— 
Contingent consideration liabilities27.3 — — 27.3 
$64.2 $— $36.9 $27.3 
Schedule of Carrying Amount and Fair Value of Long-term Debt The following table presents the carrying values and estimated fair values of the Company's debt as of the end of each period:
April 1, 2022December 31, 2021
Carrying
Value		Fair
Value		Carrying
Value		Fair
Value
Level 1:
5.75% senior notes due August 2022$610.3 $293.3 $610.3 $324.1 
4.75% senior notes due April 2023133.7 51.9 133.7 48.9 
5.625% senior notes due October 2023514.7 252.3 514.7 279.1 
5.50% senior notes due April 2025387.2 189.9 387.2 211.6 
10.00% first lien senior notes due April 2025495.0 519.6 495.0 523.7 
10.00% second lien senior notes due April 2025322.9 306.8 322.9 312.7 
Revolving credit facility900.0 900.0 900.0 900.0 
Level 2:
9.50% debentures due May 202210.4 7.7 10.4 7.7 
8.00% debentures due March 20234.4 3.2 4.4 3.2 
Term loan due September 20241,392.9 1,274.6 1,396.5 1,309.2 
Term loan due February 2025369.7 338.9 370.7 347.7 
Total Debt$5,141.2 $4,138.2 $5,145.8 $4,267.9 
Schedules of Concentration of Risk
The following table shows net sales attributable to distributors that accounted for 10.0% or more of the Company's total net sales:
Three Months Ended
April 1,
2022		March 26,
2021
CuraScript, Inc.26.0 %24.9 %
The following table shows accounts receivable attributable to distributors that accounted for 10.0% or more of the Company's gross accounts receivable at the end of each period:
April 1,
2022		December 31,
2021
AmerisourceBergen Corporation
29.2 %30.0 %
McKesson Corporation
16.8 15.0 
CuraScript, Inc.*12.7 
*Accounts receivable attributable to this distributor was less than 10.0% of total gross accounts receivable at the end of the respective period presented above.
The following table shows net sales attributable to products that accounted for 10.0% or more of the Company's total net sales:
Three Months Ended
April 1,
2022		March 26,
2021
Acthar Gel26.0 %23.1 %
INOmax20.2 24.0 
Therakos12.2 12.0